17.31 USD
-0.19 (-1.09%)
17.31 USD
0 (0%)
Taking everything into account, ADMA scores 7 out of 10 in our fundamental rating. ADMA was compared to 525 industry peers in the Biotechnology industry. ADMA has an excellent financial health rating, but there are some minor concerns on its profitability. ADMA is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings could make ADMA a good candidate for growth investing.
1. Profitability
1.1 Basic Checks
- In the past year ADMA was profitable.
- ADMA had a positive operating cash flow in the past year.
- ADMA had negative earnings in 4 of the past 5 years.
- The reported operating cash flow has been mixed in the past 5 years: ADMA reported negative operating cash flow in multiple years.
1.2 Ratios
- ADMA has a better Return On Assets (36.83%) than 98.68% of its industry peers.
- The Return On Equity of ADMA (48.57%) is better than 98.68% of its industry peers.
- ADMA has a better Return On Invested Capital (25.76%) than 98.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 36.83% | ||
| ROE | 48.57% | ||
| ROIC | 25.76% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With an excellent Profit Margin value of 42.87%, ADMA belongs to the best of the industry, outperforming 97.74% of the companies in the same industry.
- ADMA's Operating Margin of 34.19% is amongst the best of the industry. ADMA outperforms 97.36% of its industry peers.
- ADMA has a better Gross Margin (54.71%) than 76.60% of its industry peers.
- In the last couple of years the Gross Margin of ADMA has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 34.19% | ||
| PM (TTM) | 42.87% | ||
| GM | 54.71% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- ADMA has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- ADMA has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for ADMA has been increased compared to 5 years ago.
- Compared to 1 year ago, ADMA has an improved debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 20.02 indicates that ADMA is not in any danger for bankruptcy at the moment.
- ADMA's Altman-Z score of 20.02 is amongst the best of the industry. ADMA outperforms 89.25% of its industry peers.
- The Debt to FCF ratio of ADMA is 1.78, which is an excellent value as it means it would take ADMA, only 1.78 years of fcf income to pay off all of its debts.
- ADMA has a Debt to FCF ratio of 1.78. This is amongst the best in the industry. ADMA outperforms 93.77% of its industry peers.
- ADMA has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
- Looking at the Debt to Equity ratio, with a value of 0.16, ADMA is doing worse than 64.34% of the companies in the same industry.
- Although ADMA does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 1.78 | ||
| Altman-Z | 20.02 |
ROIC/WACC2.9
WACC8.87%
2.3 Liquidity
- A Current Ratio of 7.13 indicates that ADMA has no problem at all paying its short term obligations.
- ADMA has a Current ratio of 7.13. This is in the better half of the industry: ADMA outperforms 70.94% of its industry peers.
- A Quick Ratio of 3.65 indicates that ADMA has no problem at all paying its short term obligations.
- ADMA's Quick ratio of 3.65 is in line compared to the rest of the industry. ADMA outperforms 46.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.13 | ||
| Quick Ratio | 3.65 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 92.86% over the past year.
- Looking at the last year, ADMA shows a very strong growth in Revenue. The Revenue has grown by 27.62%.
- The Revenue has been growing by 70.84% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)92.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)27.62%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%12%
3.2 Future
- The Earnings Per Share is expected to grow by 33.00% on average over the next years. This is a very strong growth
- Based on estimates for the next years, ADMA will show a very strong growth in Revenue. The Revenue will grow by 21.50% on average per year.
EPS Next Y19.34%
EPS Next 2Y33.99%
EPS Next 3Y33.26%
EPS Next 5Y33%
Revenue Next Year20.85%
Revenue Next 2Y22.49%
Revenue Next 3Y22.24%
Revenue Next 5Y21.5%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- ADMA is valuated quite expensively with a Price/Earnings ratio of 32.06.
- Based on the Price/Earnings ratio, ADMA is valued cheaply inside the industry as 92.64% of the companies are valued more expensively.
- The average S&P500 Price/Earnings ratio is at 27.38. ADMA is around the same levels.
- Based on the Price/Forward Earnings ratio of 19.28, the valuation of ADMA can be described as rather expensive.
- 94.15% of the companies in the same industry are more expensive than ADMA, based on the Price/Forward Earnings ratio.
- The average S&P500 Price/Forward Earnings ratio is at 24.29. ADMA is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.06 | ||
| Fwd PE | 19.28 |
4.2 Price Multiples
- 93.21% of the companies in the same industry are more expensive than ADMA, based on the Enterprise Value to EBITDA ratio.
- ADMA's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ADMA is cheaper than 91.51% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 101.45 | ||
| EV/EBITDA | 23.6 |
4.3 Compensation for Growth
- ADMA's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- ADMA has a very decent profitability rating, which may justify a higher PE ratio.
- ADMA's earnings are expected to grow with 33.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.66
PEG (5Y)N/A
EPS Next 2Y33.99%
EPS Next 3Y33.26%
5. Dividend
5.1 Amount
- ADMA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
17.31
-0.19 (-1.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-12 2026-01-12/amc
Earnings (Next)05-05 2026-05-05
Inst Owners93.5%
Inst Owner Change-0.47%
Ins Owners2.35%
Ins Owner Change-0.43%
Market Cap4.12B
Revenue(TTM)488.56M
Net Income(TTM)209.45M
Analysts82.22
Price Target26.18 (51.24%)
Short Float %8.24%
Short Ratio5.96
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.96%
Min EPS beat(2)-1.96%
Max EPS beat(2)-1.96%
EPS beat(4)0
Avg EPS beat(4)-10.9%
Min EPS beat(4)-31.17%
Max EPS beat(4)-1.96%
EPS beat(8)3
Avg EPS beat(8)-42.78%
EPS beat(12)6
Avg EPS beat(12)-7.71%
EPS beat(16)8
Avg EPS beat(16)-5.59%
Revenue beat(2)1
Avg Revenue beat(2)-0.85%
Min Revenue beat(2)-2.51%
Max Revenue beat(2)0.81%
Revenue beat(4)2
Avg Revenue beat(4)-0.71%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)2.16%
Revenue beat(8)6
Avg Revenue beat(8)4.26%
Revenue beat(12)10
Avg Revenue beat(12)4.8%
Revenue beat(16)14
Avg Revenue beat(16)6.2%
PT rev (1m)-5.81%
PT rev (3m)-11.68%
EPS NQ rev (1m)-0.89%
EPS NQ rev (3m)4.72%
EPS NY rev (1m)-0.28%
EPS NY rev (3m)3.23%
Revenue NQ rev (1m)-0.21%
Revenue NQ rev (3m)1.63%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)0.79%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.06 | ||
| Fwd PE | 19.28 | ||
| P/S | 8.43 | ||
| P/FCF | 101.45 | ||
| P/OCF | 63.41 | ||
| P/B | 9.55 | ||
| P/tB | 9.64 | ||
| EV/EBITDA | 23.6 |
EPS(TTM)0.54
EY3.12%
EPS(NY)0.9
Fwd EY5.19%
FCF(TTM)0.17
FCFY0.99%
OCF(TTM)0.27
OCFY1.58%
SpS2.05
BVpS1.81
TBVpS1.79
PEG (NY)1.66
PEG (5Y)N/A
Graham Number4.69
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 36.83% | ||
| ROE | 48.57% | ||
| ROCE | 32.61% | ||
| ROIC | 25.76% | ||
| ROICexc | 29.27% | ||
| ROICexgc | 29.53% | ||
| OM | 34.19% | ||
| PM (TTM) | 42.87% | ||
| GM | 54.71% | ||
| FCFM | 8.31% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
F-Score7
Asset Turnover0.86
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 1.78 | ||
| Debt/EBITDA | 0.4 | ||
| Cap/Depr | 304.79% | ||
| Cap/Sales | 4.99% | ||
| Interest Coverage | 15.23 | ||
| Cash Conversion | 37.13% | ||
| Profit Quality | 19.39% | ||
| Current Ratio | 7.13 | ||
| Quick Ratio | 3.65 | ||
| Altman-Z | 20.02 |
F-Score7
WACC8.87%
ROIC/WACC2.9
Cap/Depr(3y)120.67%
Cap/Depr(5y)186.15%
Cap/Sales(3y)4.32%
Cap/Sales(5y)11.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y19.34%
EPS Next 2Y33.99%
EPS Next 3Y33.26%
EPS Next 5Y33%
Revenue 1Y (TTM)27.62%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%12%
Revenue Next Year20.85%
Revenue Next 2Y22.49%
Revenue Next 3Y22.24%
Revenue Next 5Y21.5%
EBIT growth 1Y45.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year64.1%
EBIT Next 3Y45.85%
EBIT Next 5Y36.27%
FCF growth 1Y272.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y501.56%
OCF growth 3YN/A
OCF growth 5YN/A
ADMA BIOLOGICS INC / ADMA FAQ
What is the fundamental rating for ADMA stock?
ChartMill assigns a fundamental rating of 7 / 10 to ADMA.
What is the valuation status of ADMA BIOLOGICS INC (ADMA) stock?
ChartMill assigns a valuation rating of 6 / 10 to ADMA BIOLOGICS INC (ADMA). This can be considered as Fairly Valued.
How profitable is ADMA BIOLOGICS INC (ADMA) stock?
ADMA BIOLOGICS INC (ADMA) has a profitability rating of 6 / 10.
What is the financial health of ADMA BIOLOGICS INC (ADMA) stock?
The financial health rating of ADMA BIOLOGICS INC (ADMA) is 8 / 10.